LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

Journal Article > Commentary

Reflections on participation in a trial on hydroxychloroquine as prevention for COVID-19 among health workers in Niger

Kabore Y, Vatrinet R, Guindo O, Moussa SH, Schilling WHK, Grais RF
Download
Download
Abstract
In 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a rapidly emerging virus causing the coronavirus disease 2019 (COVID-19) pandemic, had no known effective prophylaxis and no widely available proven effective antiviral treatment. Hydroxychloroquine/Chloroquine was identified as an early potential therapeutic candidate drawing on evidence from reports of both in vitro and in vivo testing. A multicountry placebo-controlled randomized trial was set to evaluate the use of hydroxychloroquine/chloroquine to prevent infection in healthcare workers and staff working in a health facility involved in COVID-19 management. One of the sites of this trial was in Niger. In Niger, of the 240 persons who were provided information about the study and with whom participation was discussed, only five participants provided their informed consent. In this article, we describe the key difficulties encountered in the conduct of this trial from the perspective of the site study team. Among the difficulties, we recognize that the epidemic context, controversy surrounding hydroxychloroquine, vaccine rollout, participants’ perspectives, and trial design had a major impact on participation.
Countries
Niger
Subject Area
Covid-19
DOI
10.4269/ajtmh.22-0606
Published Date
06-Sep-2023
PubMed ID
37580026
Languages
English
Journal
American Journal of Tropical Medicine and Hygiene
Volume / Issue / Pages
Volume 109, Issue 3, Pages 511-514
Dimensions Badge